Screener
Adaptive Biotechnologies ADPT Mrd Business — Cost of Goods Sold
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | Three Months Ended March 31, 2026 / MRD | Three Months Ended March 31, 2026 / Immune Medicine | Three Months Ended March 31, 2026 / Total | Three Months Ended March 31, 2025 / MRD | Three Months Ended March 31, 2025 / Immune Medicine(1) | Three Months Ended March 31, 2025 / Total |
|---|---|---|---|---|---|---|
| Revenue | $67,093 | $3,781 | $70,874 | $43,721 | $8,722 | $52,443 |
| Less: | ||||||
| Cost of revenue | 17,244 | * | 17,244 | 15,885 | * | 15,885 |
| Research and development | 9,226 | 13,934 | 23,160 | 9,159 | 14,488 | 23,647 |
| Sales and marketing | 24,742 | * | 24,742 | 21,413 | * | 21,413 |
| General and administrative | 12,519 | * | 12,519 | 9,502 | * | 9,502 |
| Other segment items(2) | — | 5,776 | 5,776 | — | 5,153 | 5,153 |
| Add back: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's mrd business — cost of goods sold?
- Adaptive Biotechnologies (ADPT) reported mrd business — cost of goods sold of $17.24M in Q1 2026.
- How has Adaptive Biotechnologies's mrd business — cost of goods sold changed year-over-year?
- Adaptive Biotechnologies's mrd business — cost of goods sold increased by 8.6% year-over-year, from $15.89M to $17.24M.
- What is the long-term trend for Adaptive Biotechnologies's mrd business — cost of goods sold?
- Over 3 years (2022 to 2025), Adaptive Biotechnologies's mrd business — cost of goods sold has grown at a 16.3% compound annual growth rate (CAGR), from $42.61M to $67.03M.
- What does mrd business — cost of goods sold mean?
- This captures the direct costs incurred to produce and deliver the diagnostic tests and services within the MRD business segment. It includes expenses such as laboratory reagents, personnel costs for testing, and shipping, providing insight into the direct profitability of the segment's operations.
Ask your AI about Adaptive Biotechnologies's mrd business — cost of goods sold.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude